Immusorba TR and Immusorba PH: basics of design and features of functions.
Immusorba was reported by Yamazaki et al. to be the world's first practical immunoadsorbent in 1982. Since then, this immunoadsorbent has accumulated an abundance of clinical achievements. Immusorba has such unique functions that it is used in treating various diseases and holds possibilities for application to more diseases. Immusorba was designed as an artificial receptor for rheumatoid factor (RF) based on structural analysis of heat-denaturated globulin. Subsequently, new substances that it can adsorb have been found as seen in reports on the adsorption performance of Immusorba to anti-acetylcholine receptor antibodies (anti-AChR Abs) and antiganglioside antibodies. Along with this, Immusorba has been used in treating a wide range of diseases. The greatest characteristic of Immusorba is that its adsorption capability is selective rather than specific, making it effective against a great number of diseases.
Yoshida
M
M
Tamura
Y
Y
Yamada
Y
Y
Yamawaki
N
N
Yamashita
Y
Y
D000109:Acetylcholine / Q000097:blood; D000327:Adsorption; D000936:Antigen-Antibody Complex / Q000097:blood; D004867:Equipment Design; D005732:Gangliosides / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007163:Immunosorbent Techniques / Q000295:instrumentation*; D007164:Immunosorbents / Q000737:chemistry* / Q000627:therapeutic use; D008024:Ligands; D009157:Myasthenia Gravis / Q000628:therapy; D010649:Phenylalanine / Q000737:chemistry; D011129:Polyradiculoneuropathy / Q000628:therapy; D011142:Polyvinyl Alcohol / Q000737:chemistry; D012217:Rheumatoid Factor / Q000097:blood; D014364:Tryptophan / Q000737:chemistry
D000936:Antigen-Antibody Complex; D005732:Gangliosides; D007074:Immunoglobulin G; D007164:Immunosorbents; D008024:Ligands; D010649:Phenylalanine; D014364:Tryptophan; D011142:Polyvinyl Alcohol; D012217:Rheumatoid Factor; D000109:Acetylcholine